Amphastar Pharmaceuticals, Inc. SEC Filings

Amphastar Pharmaceuticals, Inc. director Richard K. Prins reported a sale of 7,973 shares of common stock on 2026-08-11 in a sale in open market or private transaction at $20.30 per share. Following this transaction, he directly holds 29,625 shares of Amphastar common stock.

Amphastar Pharmaceuticals, Inc. director and CFO/EVP/Treasurer William J. Peters reported an options exercise and share sale. On August 7, 2026, he exercised 5,053 Employee Stock Options at an exercise price of $19.79 per share, receiving 5,053 shares of common stock and closing out that option grant. The same day, he sold 8,180 shares of common stock at $22.48 per share in a transaction described as a sale in the open market or a private transaction. The sale was executed pursuant to a Rule 10b5-1 trading plan adopted on March 10, 2026. A related holding footnote states that reported common stock holdings include 910 shares acquired on May 31, 2026 under the company’s 2014 Employee Stock Purchase Plan.

AMPH filed a notice of a proposed sale of common stock under Rule 144. The filing lists UBS Financial Services Inc as broker for a transaction involving 7,973 shares of common stock with an aggregate market value of $161,931.63, referencing 44,009,000 shares outstanding and a proposed sale date of 08/11/2026 on NASDAQ. The shares derive from multiple RSU vesting events between 2017 and 2025, including grants that vested in 2017, 2018, 2019, 2020, 2024, and 2025.

Amphastar Pharmaceuticals, Inc. reported Q2 2026 net revenues of $183,903 thousand, up from $174,414 thousand, with net income of $30,348 thousand versus $31,030 thousand a year earlier. Diluted EPS was $0.67 compared with $0.64. For the first six months, revenue rose to $355,074 thousand from $344,942 thousand, while net income decreased to $36,768 thousand from $56,315 thousand as higher cost of revenues and operating expenses reduced income from operations to $53,359 thousand from $79,477 thousand.

Cash and cash equivalents were $223,614 thousand at June 30, 2026, up from $170,177 thousand at year-end, and short-term investments were $66,509 thousand. Long-term debt, including $345,000 thousand of 2029 Convertible Notes and a $250,000 thousand term loan, was $609,564 thousand net of issuance costs. Net cash provided by operating activities improved to $99,164 thousand in the first half from $70,669 thousand, while share repurchases reached 3,656,720 shares for $74,705 thousand.

The company reached the first BAQSIMI® annual net sales milestone of $175.0 million, triggering a $100.0 million payment to Eli Lilly allocated primarily to BAQSIMI® product rights. BAQSIMI® generated $77,937 thousand of revenue in the first half, while growth in other products and new ipratropium bromide sales offset declines in Primatene MIST® and glucagon revenue. United States operations contributed $331,382 thousand of first-half revenue.

Amphastar Pharmaceuticals reported second-quarter 2026 results with net revenues of $183,903 (in thousands), up 5% from the prior-year quarter. Product performance was mixed, with declines in BAQSIMI, Primatene MIST, Epinephrine and Glucagon offset by growth in other products and the launch of Ipratropium bromide. Gross profit rose to $93,470 (in thousands), expanding gross margin to 50.8% from 49.6%.

Operating expenses increased across selling, general and administrative, and R&D, leading to GAAP net income of $30,348 (in thousands) versus $31,030 a year earlier. Diluted EPS was $0.67, while adjusted non-GAAP net income was $40,759 (in thousands) and adjusted diluted EPS was $0.91. For the first six months of 2026, net revenues were $355,074 (in thousands) and GAAP net income was $36,768 (in thousands), compared with $344,942 and $56,315 (in thousands), respectively, with operating cash flow of $99.2 million.

As of June 30, 2026, the company held cash and cash equivalents of $223,614 (in thousands), short-term investments of $66,509 (in thousands), total assets of $1,743,766 (in thousands), and stockholders’ equity of $768,157 (in thousands). The pipeline includes one ANDA and one biosimilar insulin filed with the FDA targeting markets with a combined size exceeding $1.6 billion, plus additional biosimilar and generic candidates aimed at markets exceeding $3.5 billion and over $1.2 billion, respectively.

Dimensional Fund Advisors LP, a Delaware limited partnership and registered investment adviser, reports beneficial ownership of 2,305,107 shares of Amphastar Pharmaceuticals common stock, representing 5.2% of the class as of June 30, 2026.

Dimensional has sole voting power over 2,251,660 shares and sole dispositive power over 2,305,107 shares, with no shared voting or dispositive power. The shares are held by client funds for which Dimensional or its subsidiaries provide advisory or management services, and Dimensional disclaims beneficial ownership beyond Section 13(d) reporting. No individual fund’s interest exceeds 5% of the class.

Pierce Anthony T reported acquisition or exercise transactions in this Form 4 filing.

Amphastar Pharmaceuticals director Anthony T. Pierce received equity compensation on July 9, 2026, consisting of 7,886 restricted stock units and 16,646 stock options. All RSUs and options vest on July 9, 2027, with the options exercisable at $19.02 per share and expiring on July 9, 2036. These are grants, not open‑market purchases or sales.

Amphastar Pharmaceuticals, Inc. identifies Anthony T. Pierce as a director and reporting person in an initial insider ownership report. The disclosure shows no equity or derivative holdings and no buy, sell, exercise, or other transactions reported for him in Amphastar securities.